BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30418174)

  • 1. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
    Johmura Y; Maeda I; Suzuki N; Wu W; Goda A; Morita M; Yamaguchi K; Yamamoto M; Nagasawa S; Kojima Y; Tsugawa K; Inoue N; Miyoshi Y; Osako T; Akiyama F; Maruyama R; Inoue JI; Furukawa Y; Ohta T; Nakanishi M
    J Clin Invest; 2018 Dec; 128(12):5603-5619. PubMed ID: 30418174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
    Johmura Y; Harris AS; Ohta T; Nakanishi M
    Cancer Sci; 2020 Aug; 111(8):2718-2725. PubMed ID: 32536008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis.
    Suzuki N; Johmura Y; Wang TW; Migita T; Wu W; Noguchi R; Yamaguchi K; Furukawa Y; Nakamura S; Miyoshi I; Yoshimori T; Ohta T; Nakanishi M
    Autophagy; 2021 Nov; 17(11):3776-3793. PubMed ID: 33706682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence.
    Johmura Y; Sun J; Kitagawa K; Nakanishi K; Kuno T; Naiki-Ito A; Sawada Y; Miyamoto T; Okabe A; Aburatani H; Li S; Miyoshi I; Takahashi S; Kitagawa M; Nakanishi M
    Nat Commun; 2016 Feb; 7():10574. PubMed ID: 26868148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCF
    Bai J; Wu K; Cao MH; Yang Y; Pan Y; Liu H; He Y; Itahana Y; Huang L; Zheng JN; Pan ZQ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11754-11763. PubMed ID: 31138683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N; Nakayama Y; Yamaguchi N
    J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression.
    Sun R; Xie HY; Qian JX; Huang YN; Yang F; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2018 Sep; 78(18):5274-5286. PubMed ID: 29945959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
    Tan MK; Lim HJ; Harper JW
    Mol Cell Biol; 2011 Sep; 31(18):3687-99. PubMed ID: 21768309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway.
    Zheng Y; Chen H; Zhao Y; Zhang X; Liu J; Pan Y; Bai J; Zhang H
    Invest New Drugs; 2020 Feb; 38(1):20-28. PubMed ID: 30887251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.
    Wardell SE; Nelson ER; Chao CA; McDonnell DP
    Clin Cancer Res; 2013 May; 19(9):2420-31. PubMed ID: 23536434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells.
    Wang L; Sun J; Yin Y; Sun Y; Ma J; Zhou R; Chang X; Li D; Yao Z; Tian S; Zhang K; Liu Z; Ma Z
    Cell Death Dis; 2021 Feb; 12(2):149. PubMed ID: 33542201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.
    Guo F; Liu J; Han X; Zhang X; Lin T; Wang Y; Bai J; Han J
    Int J Biol Sci; 2019; 15(3):647-656. PubMed ID: 30745851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.
    Zhang J; Zhou C; Jiang H; Liang L; Shi W; Zhang Q; Sun P; Xiang R; Wang Y; Yang S
    Cell Death Dis; 2017 Apr; 8(4):e2732. PubMed ID: 28383555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
    Zheng L; Meng X; Li X; Zhang Y; Li C; Xiang C; Xing Y; Xia Y; Xi T
    FASEB J; 2018 Feb; 32(2):588-600. PubMed ID: 28939591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM4B is a master regulator of the estrogen receptor signalling cascade.
    Gaughan L; Stockley J; Coffey K; O'Neill D; Jones DL; Wade M; Wright J; Moore M; Tse S; Rogerson L; Robson CN
    Nucleic Acids Res; 2013 Aug; 41(14):6892-904. PubMed ID: 23723241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.